Comparison of Different Methods for Measuring Urinary Oxalate and Citrate: An Observational Study (Comparison of)
Novel Derivatization-Based HPLC for Urinary Oxalate and Citrate: A Superior Clinical Alternative to Ion Chromatography
This observational study aims to compare three different laboratory methods for measuring urine oxalate and citrate concentrations. The primary objective is to evaluate whether an improved High-Performance Liquid Chromatography (HPLC) method-using a novel derivatization reagent-can achieve similar accuracy to the gold standard Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) while offering advantages in cost, speed, and ease of use in routine clinical settings.
The study will involve the collection of morning urine samples from both healthy volunteers and patients with urolithiasis (urinary stones). Each urine sample will be tested using the following three methods:
- Modified High-Performance Liquid Chromatography (HPLC): This method builds on traditional HPLC technology by incorporating a novel derivatization reagent to enhance the sensitivity and accuracy of detecting oxalate and citrate. The improved HPLC method is designed to be less time-consuming and more cost-effective, which could make it a viable option for regular clinical use.
- Ion Chromatography (IC): Widely used in many hospital laboratories, the IC method detects urine oxalate and citrate without the need for a derivatization step. While this method is straightforward and convenient, its sensitivity and accuracy are expected to be lower compared to LC-MS/MS and the modified HPLC method.
- Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS): LC-MS/MS is currently considered the gold standard for measuring urine oxalate and citrate due to its high sensitivity and specificity. However, the method requires expensive equipment and involves complex procedures, limiting its routine application in most clinical laboratories.
Participants will provide urine samples, which will be divided and analyzed using all three methods simultaneously. The study will assess the correlation and consistency between the methods, with a particular focus on comparing the modified HPLC method to LC-MS/MS. Statistical analyses, including Bland-Altman analysis and linear regression, will be used to determine the agreement between the measurement techniques.
This study is non-interventional and involves only the collection of urine samples, posing minimal risk to participants. Informed consent will be obtained from all participants after they are fully briefed about the study objectives, procedures, and any potential risks. All collected data will be managed confidentially and analyzed rigorously to ensure the reliability of the findings.
If the modified HPLC method demonstrates comparable accuracy to LC-MS/MS, it could provide a more accessible, cost-effective, and timely option for routine clinical measurement of urinary oxalate and citrate. Such an improvement in laboratory diagnostics may support better clinical decision-making in the prevention and management of urinary stone disease, ultimately benefiting patient care.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510230
- Department of Urology and Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Imaging evidence indicating the presence of urinary stones (stone patient group).
- Imaging evidence indicating the absence of urinary stones (control group).
Exclusion Criteria:
1. Patients who are unable to understand or complete the study documentation.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Healthy people
|
|
Patients with Urolithiasis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of Uric Acid Measurements from Three Methods
Time Frame: Baseline sample analysis, with all measurements completed within 24 hours of sample collection.
|
The primary outcome is to compare the uric acid measurement results obtained from three analytical methods: modified High-Performance Liquid Chromatography (HPLC) using a novel derivatization reagent, Ion Chromatography (IC), and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS).
This outcome will be evaluated by determining the mean differences, 95% confidence intervals, and correlations among the three methods using Bland-Altman analysis and linear regression.
The goal is to assess whether the modified HPLC method can reliably reflect uric acid levels comparable to the LC-MS/MS gold standard.
|
Baseline sample analysis, with all measurements completed within 24 hours of sample collection.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparison of Urinary Citrate Measurements from Three Methods
Time Frame: Baseline sample analysis, with all measurements completed within 24 hours of sample collection.
|
The secondary outcome is to evaluate and compare the urinary citrate concentration results obtained from the three methods: modified HPLC, Ion Chromatography (IC), and LC-MS/MS.
The analysis will include calculating mean differences, 95% confidence intervals, and assessing the degree of correlation among the methods using statistical tools such as Bland-Altman plots and linear regression.
This outcome will help determine the consistency and reliability of citrate measurements across the different analytical techniques.
|
Baseline sample analysis, with all measurements completed within 24 hours of sample collection.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- ES-2024-242-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.